PTLA’s BLA submission for PRT4445 in 2015 will include data on the reversibility of all FXa inhibitors* as well as Lovenox and other LMWH’s. (Source: Today’s MS webcast.) Good luck with that, LOL; my opinion in #msg-91053501 remains unchanged.
*Xarelto, Elliquis, Edoxaban, Betrixaban.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”